

some of the proposed information collection requirements. The field test has been completed with favorable results and a report on the field test will be provided with the proposed reporting specifications upon request.

Call the Administration on Aging, Office of State and Community Programs at (202) 619-0011 for copies of the proposed reporting requirements and a report on the field test. Written comments and recommendations for the proposed information collection requirements should be sent within 60 days of the publication of this notice directly to the following address: Edwin L. Walker, Director, Office of Program Operations and Development, Administration on Aging, 330 Independence Avenue SW., Washington, DC 20201.

Dated: February 7, 1996.

William F. Benson,

Deputy Assistant Secretary for Governmental Affairs and Elder Rights.

[FR Doc. 96-3152 Filed 2-12-96; 8:45 am]

BILLING CODE 4150-04-M

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Institute for Occupational Safety and Health: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 9 a.m.-5:30 p.m., March 11, 1996.

Place: The Washington Court Hotel, Ballroom East, 525 New Jersey Avenue NW., Washington, DC 20001.

Status: Open to the public, limited only by the space available.

Purpose: The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: Agenda items include a report from the Director of NIOSH, an update on the National Occupational Research Agenda, NIOSH Agriculture Program, a report on workplace violence, a report from the National Foundation for the Centers for Disease Control and Prevention, Inc., an evaluation of the construction program, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

CONTACT PERSON FOR MORE INFORMATION: Bryan Hardin, Ph.D., Acting Executive Secretary, BSC, NIOSH, and Acting

Deputy Director, NIOSH, CDC, 1600 Clifton Road, NE, Mailstop D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: February 6, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-3120 Filed 2-12-96; 8:45 am]

BILLING CODE 4163-19-M

Centers for Disease Control and Prevention

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on State and Community Health Statistics: Meeting

Pursuant to Public Law 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meeting.

Name: NCVHS Subcommittee on State and Community Health Statistics.

Time and Date: 9 a.m.-5 p.m., March 14, 1996.

Place: Room 503A-529A, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee will receive testimony from public and private agencies and/or individuals concerning the methods and materials for community health assessment.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8:30 and 9 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone number 301/436-7050.

Dated: February 6, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-3119 Filed 2-12-96; 8:45 am]

BILLING CODE 4163-18-M

Centers for Disease Control and Prevention

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Mental Health Statistics: Meeting

Pursuant to Pub. L. 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meeting.

Name: NCVHS Subcommittee on Mental Health Statistics.

Time and Date: 9 a.m.-5 p.m., February 28, 1996.

Place: Room 503A-529A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee will continue deliberations with respect to enrollment and encounter data, consider new epidemiological findings regarding alcohol abuse, and review new developments in managed care.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8:30 and 9 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone number 301/436-7050.

Dated: February 8, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-3287 Filed 2-12-96; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 96N-0029]

Reed & Carnrick Pharmaceuticals, et al.; Withdrawal of Approval of 2 New Drug Applications and 67 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 2 new drug applications (NDA's) and 67 abbreviated new drug applications (ANDA's). The holders of

the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: March 14, 1996.

FOR FURTHER INFORMATION CONTACT: Lola Batson, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1038.

SUPPLEMENTARY INFORMATION: The holders of the NDA's and ANDA's listed

in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
6-309	Kwell Lotion/Kwell Cream	Reed & Carrick Pharmaceuticals, 257 Cornelison Ave., Jersey City, NJ 07302-3198.
10-718	Kwell Shampoo	Do.
70-021	Metronidazole Tablets, USP, 250 milligrams (mg)	Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233.
70-205	Diphenhydramine Hydrochloride Cough Syrup, 12.5 mg/5 milliliters (mL).	Barre-National, Inc., Johns Hopkins Bayview Research Campus, 333 Cassell Dr., suite 3500, Baltimore, MD 21224.
70-593	Metronidazole Tablets, USP, 500 mg	Halsey Drug Co., Inc.
70-635	Indomethacin Capsules, USP, 50 mg	Do.
70-782	Indomethacin Capsules, USP, 25 mg	Do.
70-906	Metoclopramide Tablets, USP, 10 mg	Do.
71-027	Ibuprofen Tablets, USP, 200 mg	Do.
71-028	Ibuprofen Tablets, USP, 300 mg	Do.
71-029	Ibuprofen Tablets, USP, 400 mg	Do.
71-030	Ibuprofen Tablets, USP, 600 mg	Do.
71-292	Diphenhydramine Hydrochloride Syrup, 12.5 mg/5 mL	L. Perrigo Co., 117 Water St., Allegan, MI 49010.
71-434	Lorazepam Tablets, USP, 0.5 mg	Halsey Drug Co., Inc.
71-435	Lorazepam Tablets, USP, 1 mg	Do.
71-436	Lorazepam Tablets, USP, 2 mg	Do.
71-753	Methyldopa Tablets, USP, 500 mg	Do.
71-772	Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP, 80 mg/ 25 mg.	Warner Chilcott, 201 Tabor Rd., Morris Plains, NJ 07950.
72-137	Ibuprofen Tablets, USP, 800 mg	Halsey Drug Co., Inc.
72-646	Diphenhydramine Hydrochloride Syrup, 12.5 mg/5 mL	Silarx Pharmaceuticals, Inc., 19 West St., P.O. Box 449, Spring Valley, NY 10977.
80-015	Propylthiouracil Tablets, USP, 50 mg	Halsey Drug Co., Inc.
80-304	Prednisolone Tablets, USP, 1 mg, 2.5 mg, and 5 mg	Do.
80-498	Rauwolfia Serpentina Tablets, USP, 50 mg and 100 mg	Do.
83-518	Dienestrol Cream, USP, 0.01%	Marion Merrill Dow, Inc., P.O. Box 9627, Kansas City, MO 64134-0627.
83-538	Propoxyphene Hydrochloride Capsules, USP, 65 mg	Halsey Drug Co., Inc.
83-546	Estradiol Valerate Injection, USP, 10 mg/mL	Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043-4705.
83-583	Quinine Sulfate Tablets, USP, 200 mg	Halsey Drug Co., Inc.
83-598	Folic Acid Tablets, USP, 1 mg	Do.
83-871	Acetaminophen and Codeine Phosphate Tablets, USP, 300 mg/15 mg.	Do.
83-872	Acetaminophen and Codeine Phosphate Tablets, USP, 300 mg/30 mg.	Do.
83-891	Hydrochlorothiazide Tablets, USP, 50 mg	Do.
84-677	Pentobarbital Sodium Capsules, USP, 100 mg	Do.
84-685	Chlordiazepoxide Hydrochloride Capsules, USP, 25 mg	Do.
84-719	Butabarbital Sodium Tablets, USP, 15 mg and 30 mg	Do.
84-723	Butabarbital Sodium Elixir, USP, 30 mg/5 mL	Do.
85-067	Hydrochlorothiazide Tablets, USP, 25 mg	Inwood Laboratories, Inc., 909 Third Ave., New York, NY 10022-4731.
85-148	Theophylline Sodium Glycinate Tablets, USP, 150 mg	Sandoz Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936-1080.
85-211	Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP, 2.5 mg/0.025 mg.	Halsey Drug Co., Inc.
85-339	Chlordiazepoxide Hydrochloride Capsules, USP, 10 mg	Do.
85-340	Chlordiazepoxide Hydrochloride Capsules, USP, 5 mg	Do.
85-409	Aminophylline Tablets, USP, 100 mg	Vintage Pharmaceuticals, Inc., 3241 Woodpark Blvd., Charlotte, NC 28206.
85-410	Aminophylline Tablets, USP, 200 mg	Do.
85-922	Amitriptyline Hydrochloride Tablets, USP, 25 mg	Halsey Drug Co., Inc.
86-194	Erythryl Tetranitrate Tablets (chewable), 10 mg	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709-2700.
86-504	Hydrochlorothiazide Tablets, USP, 25 mg	Halsey Drug Co., Inc.
86-549	Acetaminophen and Codeine Phosphate Tablets, USP, 300 mg/60 mg.	Do.
86-588	Phenobarbital with Belladonna Alkaloids Tablets	Do.

Application no.	Drug	Applicant
86-652	Phenobarbital with Belladonna Alkaloids Elixir	Solvay Pharmaceuticals, 901 Sawyer Rd., Marietta, GA 30062.
86-662	Phenobarbital with Belladonna Alkaloids Elixir	Pharmaceutical Associates, P.O. Box 128, Conestee, SC 29636.
87-136	Hydrocortisone Cream, USP, 0.5%, 1%, and 2.5%	Westwood-Squibb Pharmaceuticals, 100 Forest Ave., Buffalo, NY 14213-1091.
87-200	Aminophylline Injection USP, 25 mg/mL	Fujisawa USA, Inc., 3 Parkway North, 3d Floor, Deerfield, IL 60015-2548.
87-480	Prednisone Tablets, USP, 20 mg	Halsey Drug Co., Inc.
87-802	Dipyridamole Tablets, USP, 25 mg	Do.
87-803	Dipyridamole Tablets, USP, 75 mg	Do.
87-914	Diphenhydramine Hydrochloride Capsules, USP, 50 mg	Do.
88-048	Fluocinolone Acetonide Topical Solution, USP, 0.01%	Pharmaderm, Division of Altana, Inc., 60 Baylis Rd., Melville, NY 11747.
88-192	Tripolidine and Pseudoephedrine Hydrochloride Tablets, USP, 2.5 mg/60 mg.	Halsey Drug Co., Inc.
88-466	Dipyridamole Tablets, USP, 50 mg	Do.
88-662	Chlorpropamide Tablets, USP, 250 mg	Do.
89-218	Hydralazine Hydrochloride Tablets, USP, 10 mg	Do.
89-321	Chlorpropamide Tablets, USP, 100 mg	Do.
89-366	Hydroxyzine Hydrochloride Tablets, USP, 10 mg	Do.
89-396	Hydroxyzine Hydrochloride Tablets, USP, 50 mg	Do.
89-448	Butalbital, Aspirin, and Caffeine Tablets, USP, 50 mg/325 mg/40 mg.	Do.
89-465	Leucovorin Calcium for Injection, 50 mg/vial	Burroughs Wellcome Co.
89-476	Quinidine Gluconate Extended-Release Tablets, USP, 324 mg.	Halsey Drug Co., Inc.
89-738	Chlorthalidone Tablets, USP, 25 mg (Peach)	Mutual Pharmaceutical Co., Inc., 1100 Orthodox St., Philadelphia, PA 19124-3131.
89-739	Chlorthalidone Tablets, USP, 50 mg (Aqua)	Do.
89-833	Leucovorin Calcium for Injection, 25 mg/vial	Burroughs Wellcome Co.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the applications listed above, and all amendments and supplements thereto, is hereby withdrawn, effective March 14, 1996.

Dated: January 29, 1996.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 96-3077 Filed 2-12-96; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Heart, Lung, and Blood Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Lymphocyte ADP-Ribosyltransferase and its Corresponding Hydrolase as a Potential Target for Therapeutic Intervention in Diseases of the Immune System

AGENCY: Department of Health and Human Services, National Institutes of Health.

ACTION: Notice.

SUMMARY: The National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health is seeking capability statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) on the further characterization of lymphocyte ADP-ribosyltransferase as a potential target for therapeutic intervention in diseases of the immune system. This project is with the National Heart, Lung, and Blood Institute, Division of Intramural Research, Pulmonary-Critical Care Medicine Branch, located in Bethesda, Maryland.

The goal is to use the respective strength of both partners in (1) identifying molecular targets of ADP-ribosylation in lymphocytes and muscle cells, and, (2) evaluating the potential use of this enzyme and its various substrates as targets of novel treatment modalities in certain diseases of the immune system and in hematological, pulmonary, and cardiac diseases.

ADP-ribosylation is a post-translational modification of proteins, in which the ADP-ribose moiety of NAD is transferred to a protein acceptor. In the case of certain bacterial toxins (e.g. pertussis toxin, cholera toxin), ADP-ribosylation modifies hormone action on their human target cells and is the

mechanism responsible for toxin action and, in large part, the pathogenesis of disease. Human cells have endogenous ADP-ribosylation pathways: the pathways are composed of enzymes that place ADP-ribose on proteins, ADP-ribosyltransferases, which catalyze a reaction similar to the bacterial toxins, and enzymes that remove ADP-ribose, ADP-ribosylarginine hydrolases. Hence, ADP-ribosylation may be reversible, with ADP-ribosyltransferases and ADP-ribosylarginine hydrolases serving as components of a regulatory cycle.

ADP-ribosyltransferases have been found in peripheral blood mononuclear cells and in skeletal and cardiac muscle. These enzymes have been cloned and are identical. The transferases, are linked to the cell surface through glycosylphosphatidylinositol (GPI)-anchors. In the muscle, they ADP-ribosylate the extracellular domain of an integrin and hence may participate in the regulation of cell-matrix interactions. Other data suggest that ADP-ribosylation may be involved in the regulation of cytotoxic lymphocyte activity. The cell surface location of the transferases may facilitate their specific targeting by chemotherapeutic agents. In particular, they may be targeted in diseases where lymphocytes are readily